U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H19N3O3S
Molecular Weight 345.416
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMEPRAZOLE

SMILES

COC1=CC2=C(NC(=N2)[S+]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1

InChI

InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)

HIDE SMILES / InChI
Molecular Formula C17H19N3O3S
Molecular Weight 345.416
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Omeprazole belongs to a class of antisecretory compounds, which suppress gastric acid secretion by specific inhibition of the H+ /K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Omeprazole is used under brand names Prilosec and Losec for treatment of duodenal ulcer in adults, gastric ulcer in adults, Gastroesophageal Reflux Disease. In addition it used for maintenance of healing of erosive esophagitis in pediatric patients and adults and for treatment of pathological hypersecretory conditions in adults (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis). The most frequent significant adverse effects occurring in at least of patients include headache; upper respiratory tract infection, abdominal pain, diarrhea, back pain, weakness and rash.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available

Approval Year

1989
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1.20597119E12
Primary
Approved
8429
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1.20597119E12
Primary
Approved
8429
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

6.217344E11
Primary
Approved
8429
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1.20597119E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
668 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1220 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1179 nM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2350532
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1200 nM*h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01361217
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.58 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2350532
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
Other AEs: Nausea, Diarrhoea...
Other AEs:
Nausea (7%)
Diarrhoea (6%)
Headache (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (6.9%)
Abdominal pain (5.2%)
Nausea (4%)
Diarrhea (3.7%)
Vomiting (3.2%)
Flatulence (2.7%)
Esophageal acid reflux (1.9%)
Upper respiratory infection (1.9%)
Constipation (1.5%)
Dizziness (1.5%)
Rash (1.5%)
Asthenia (1.3%)
Back pain (1.1%)
Cough (1.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
Diarrhoea 6%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
Nausea 7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
https://pubmed.ncbi.nlm.nih.gov/11563998/
Back pain 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Cough 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Asthenia 1.3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Constipation 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Dizziness 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Rash 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Esophageal acid reflux 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Upper respiratory infection 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Flatulence 2.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Vomiting 3.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Diarrhea 3.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Nausea 4%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Abdominal pain 5.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Headache 6.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

substrate
1737
inhibitor
1767

substrate
1037
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461

CYP2C19
1478

CYP1A2
1524

BCRP
699

OATP1B1
788

OAT3
642

OAT1
599

MATE1
306

MATE2
263

OCT2
647

OCT1
512

OCT3
150
P-gp
1537

CYP2C19
991

CYP2C8
693

CYP2C18
138
MRP3
53

CYP1A1
108

CYP1A2
701

CYP1B1
51
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 weak [Ki 150 uM]
weak (co-administration study)
Comment: Omeprazole exerts a concentration-dependent inhibition of CYP1A2 activity in man. However, even after single oral doses up to 80 mg, this effect is weak and without clinical relevance
CYP3A4
1925
 weak [Ki 367.5 uM]
CYP2D6
1891
 weak [Ki 745.1 uM]
OCT1
543
 yes [IC50 15.7 uM]
BCRP
773
 yes [IC50 17.6 uM]
P-gp
1650
 yes [IC50 17.7 uM]
OCT3
150
 yes [IC50 22 uM]
OAT1
603
 yes [IC50 4.32 uM]
OCT2
648
 yes [IC50 6.7 uM]
OAT3
644
 yes [IC50 6.8 uM]
OATP1B1
803
 yes [IC50 84.3 uM]
unlikely (co-administration study)
Comment: Coaministration with simvastatin acid unlikely results in DDIs
CYP2C19
1553
 yes [Ki 7.1 uM]
yes (co-administration study)
Comment: Omeprazole increased Cmax and AUC of cilostazol by 18% and 26% respectively
CYP1A1
218
 yes
CYP1A2
1692
 yes
CYP1B1
67
 yes
CYP2C9
1819
 yes
MATE1
308
 yes
MATE2
263
 yes
MRP3
207
 yes
yes (expression study)
Comment: livers of patients treated with omeprazole showed higher MRP3 protein expression
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
991
 major
yes (co-administration study)
Comment: When voriconazole was given with omeprazole to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times and 4 times, respectively
CYP3A4
1737
 major
yes (co-administration study)
Comment: Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels. In a cross-over study in 12 healthy male subjects, St John’s wort, an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (Cmax and AUC decreased by 49.6% and 43.9%, respectively)
CYP2C18
138
 minor
CYP2C8
693
 minor
CYP2C9
1037
 minor
P-gp
1537
 no
PubMed

PubMed

TitleDatePubMed
Omeprazole-induced delirium.
2000 Jan
Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
2000 Mar
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
2001
Pantoprazole and cyclosporine or tacrolimus.
2001 Apr
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus.
2001 Apr
[Suppressive effect of lansoprazole on anti-Candida activity of murine macrophages].
2001 Feb
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
2001 Feb
[Usefulness of new triple therapy containing PPI].
2001 Feb
[Selection of antibiotics and planning of eradication for H. pylori infection].
2001 Feb
Relaxation induced by omeprazole does not change in diabetic rabbit corpus cavernosum.
2001 Feb
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
2001 Jan
[Heartburn. Only a harmless symptom?].
2001 Mar 8
New OTC drugs and devices 2000: a selective review.
2001 Mar-Apr
Microsatellite instability at D18S61 is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication.
2001 Mar-Apr
Patents

Patents

06245913
2
07176319
2
07435826
2
08173817
2
08748619
2
JP2001526211A
8
JP2003500442A
8
JP2003515526A
462
JP2004043494A
2
JP2007161734A
2
JP2007507425A
11
JP4708327B2
47
JP4795435B2
2
JPH05294831A
2
JPS62258320A
2

Sample Use Guides

In Vivo Use Guide
Active Duodenal Ulcer: 20 mg Once daily for 4 weeks. Some patients may require an addition 4 weeks. Gastric Ulcer: oral dose is 40 mg once daily for 4-8 weeks. Gastroesophageal Reflux Disease: The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.
Route of Administration: Oral
In Vitro Use Guide
Pretreatment of omeprazole (10-6 - 10-4M) dose-dependently inhibits neutrophil adherence and respiratory burst induced by H. pylori. These evidences imply that omeprazole may exhibit a beneficial effect on H. pylori-associated gastric mucosal damage caused by activated neutrophils.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:41:37 UTC 2023
Edited
by admin
on Fri Dec 15 17:41:37 UTC 2023
Record UNII
KG60484QX9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMEPRAZOLE
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
OMEPRAZOLE [JAN]
Common Name English
OMEPRAZOLE COMPONENT OF ZEGERID
Common Name English
5-METHOXY-2-(((4-METHOXY-3,5,-DIMETHYL-2-PYRIDINYL)-METHYL)SULPHINYL)-1H-BENZIMIDAZOLE
Common Name English
NSC-759192
Code English
NSC-751450
Code English
1H-BENZIMIDAZOLE, 5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
OMEPRAZOLE COMPONENT OF YOSPRALA
Brand Name English
OMEPRAZOLE [USP-RS]
Common Name English
OMEPRAZOLE [USP MONOGRAPH]
Common Name English
OMEPRAZOLE [HSDB]
Common Name English
OMEPRAZOLE [MART.]
Common Name English
OMEPRAZOLE [USP IMPURITY]
Common Name English
LOSEC
Brand Name English
H-168/68
Code English
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole
Systematic Name English
OMEPRAZOLE [MI]
Common Name English
OMEPRAZOLE [GREEN BOOK]
Common Name English
ZEGERID COMPONENT OMEPRAZOLE
Common Name English
(RS)-6-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL) METHYLSULFINYL)-1H-BENZO(D)IMIDAZOLE
Systematic Name English
omeprazole [INN]
Common Name English
H 168/68
Code English
Omeprazole [WHO-DD]
Common Name English
OMEPRAZOLE [VANDF]
Common Name English
OMEPRAZOLE [ORANGE BOOK]
Common Name English
OMEPRAZOLE [USAN]
Common Name English
YOSPRALA COMPONENT OMEPRAZOLE
Brand Name English
Classification Tree Code System Code
WHO-ATC A02BD05
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
WHO-VATC QA02BD01
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
WHO-ATC A02BC01
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
WHO-VATC QA02BD05
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
CFR 21 CFR 520.1615
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
LIVERTOX NBK548771
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
NDF-RT N0000175525
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
FDA ORPHAN DRUG 446014
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
WHO-ATC A02BD01
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
WHO-VATC QA02BC01
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
NCI_THESAURUS C29723
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 17.1
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
NDF-RT N0000000147
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
Code System Code Type Description
MERCK INDEX
m8209
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY Merck Index
MESH
D009853
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
RXCUI
7646
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY RxNorm
NSC
751450
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
NCI_THESAURUS
C716
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
CAS
73590-58-6
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
WIKIPEDIA
OMEPRAZOLE
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
PUBCHEM
4594
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
RS_ITEM_NUM
1478505
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
USAN
X-3
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
EPA CompTox
DTXSID6021080
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
DRUG BANK
DB00338
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
FDA UNII
KG60484QX9
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
NSC
759192
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
HSDB
3575
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
EVMPD
SUB09439MIG
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL1503
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
IUPHAR
4279
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
LACTMED
Omeprazole
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
DAILYMED
KG60484QX9
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
SMS_ID
100000092047
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
DRUG CENTRAL
1990
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
INN
5081
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
CHEBI
7772
Created by admin on Fri Dec 15 17:41:37 UTC 2023 , Edited by admin on Fri Dec 15 17:41:37 UTC 2023
PRIMARY
Related Record Type Details
MRP-2
METABOLIC ENZYME -> INHIBITOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
Structure of OMEPRAZOLE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
POTASSIUM-TRANSPORTING ATPASE ALPHA CHAIN 1
TARGET -> INHIBITOR
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INDUCER
MRP-3
TRANSPORTER -> INHIBITOR
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7
METABOLIC ENZYME -> INDUCER
Structure of OMEPRAZOLE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
MRP-2
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C19
METABOLIC ENZYME -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of OMEPRAZOLE MAGNESIUM
SALT/SOLVATE -> PARENT
Structure of OMEPRAZOLE SODIUM
SALT/SOLVATE -> PARENT
CYTOCHROME P450 1A2 (CANINE)
METABOLIC ENZYME -> INDUCER
Structure of OMEPRAZOLE, (R)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of 2-(2-HYDROXYSULFANYL-4-METHOXY-3,5-DIMETHYL-PYRIDIN-1-IUM-1-YL)-5-METHOXY-1H-BENZIMIDAZOLE
METABOLITE ACTIVE -> PRODRUG
Structure of OMEPRAZOLE SULFONE
METABOLITE INACTIVE -> PARENT
SUBSTRATE
Structure of 3,10-DIMETHOXY-2,4-DIMETHYL-5H-BENZO(4,5)IMIDAZO(1,2-B)PYRIDO(1,2-D)(1,2,4)THIADIAZIN-13-IUM
METABOLITE ACTIVE -> PRODRUG
Structure of 5'-HYDROXYOMEPRAZOLE, R-
METABOLITE INACTIVE -> PARENT
Structure of 3-HYDROXYOMEPRAZOLE
METABOLITE INACTIVE -> PARENT
Structure of 5-O-DESMETHYLOMEPRAZOLE
METABOLITE -> PARENT
Structure of 4-METHOXY-6-(((6-METHOXY-1H-BENZIMIDAZOL-2-YL)SULFINYL)METHYL)-5-METHYL-3-PYRIDINECARBOXYLIC ACID
METABOLITE INACTIVE -> PARENT
Structure of 5-O-DESMETHYLESOMEPRAZOLE
METABOLITE INACTIVE -> PARENT
Structure of UFIPRAZOLE
METABOLITE -> PARENT
Related Record Type Details
Structure of OMEPRAZOLE PYRIDONE ACID
IMPURITY -> PARENT
Structure of OMEPRAZOLE SULFONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of H-180/29
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of UFIPRAZOLE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of OMEPRAZOLE-N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 8-METHOXY-1,3-DIMETHYL-12-THIOXOPYRIDO(1',2':3,4)IMIDAZO(1,2-A)BENZIMIDAZOL-2(12H)-ONE
IMPURITY -> PARENT
Impurities F and G: maximum 350 ppm for the sum of the contents
EP
Structure of 9-METHOXY-1,3-DIMETHYL-12-THIOXOPYRIDO(1',2':3,4)IMIDAZO(1,2-A)BENZIMIDAZOL-2(12H)-ONE
IMPURITY -> PARENT
Impurities F and G: maximum 350 ppm for the sum of the contents
EP
Structure of N-Methyl Omeprazole
IMPURITY -> PARENT
Structure of 5-METHOXY-2-MERCAPTOBENZIMIDAZOLE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of OMEPRAZOLE SULFONE N-OXIDE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of DESULFOXIDE 4-DEMETHYL OMEPRAZOLE
IMPURITY -> PARENT
Structure of 4-DESMETHOXY-4-CHLOROOMEPRAZOLE
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
Structure of 2-(2-HYDROXYSULFANYL-4-METHOXY-3,5-DIMETHYL-PYRIDIN-1-IUM-1-YL)-5-METHOXY-1H-BENZIMIDAZOLE
ACTIVE MOIETY
Structure of 3,10-DIMETHOXY-2,4-DIMETHYL-5H-BENZO(4,5)IMIDAZO(1,2-B)PYRIDO(1,2-D)(1,2,4)THIADIAZIN-13-IUM
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Hepatic Imairment
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966